GRACE: Long-Term Outcomes in NSTEMI and UA No Better than in STEMI

2010 ◽  
Vol 10 (8) ◽  
pp. 33-33
Author(s):  
A. Jacobson ◽  
K. A. A. Fox
Keyword(s):  
Long Term Outcomes ◽  
Better Than

scholarly journals MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD

Blood ◽  
2018 ◽  
Vol 131 (25) ◽  
pp. 2846-2855 ◽  
Author(s):  
Hannah Major-Monfried ◽  
Anne S. Renteria ◽  
Attaphol Pawarode ◽  
Pavan Reddy ◽  
Francis Ayuk ◽  
...  
Keyword(s):  
Clinical Response ◽  
Acute Gvhd ◽  
Steroid Treatment ◽  
Prognostic Biomarkers ◽  
Long Term Outcomes ◽  
Steroid Resistant ◽  
Key Points ◽  
Better Than

Key Points Biomarker scores generated after 1 week of steroid treatment of GVHD are prognostic. Biomarkers reflect prognosis better than early clinical response to GVHD treatment.

Long-Term Outcomes in Automated Peritoneal Dialysis: Similar or Better than in Continuous Ambulatory Peritoneal Dialysis?

2009 ◽  
Vol 29 (2_suppl) ◽  
pp. 111-114 ◽  
Author(s):  
Rajnish Mehrotra
Keyword(s):  
Peritoneal Dialysis ◽  
Early Period ◽  
Residual Renal Function ◽  
Maintenance Hemodialysis ◽  
Long Term Outcomes ◽  
The World ◽  
Renal Clearances ◽  
Clinically Significant ◽  
Better Than

In many parts of the world, a progressively larger proportion of chronic peritoneal dialysis (PD) patients are being treated with automated PD (APD). Increasingly, the decision to use APD is being dictated by patient and physician preference rather than being based on medical considerations. It is important to determine if the PD modality has any effect on long-term patient outcomes. Studies examining the effects of APD on residual renal function have been inconsistent, and the effect of cycler use on native renal clearances, if any, is small and probably not clinically significant. The preponderance of the evidence suggests that peritonitis rates are somewhat lower in APD patients than in patients treated with continuous ambulatory PD (CAPD). Two of three recent studies indicated that the risk for transfer to maintenance hemodialysis may be lower in APD patients, particularly in the early period after starting chronic PD. However, the risk for death in patients treated with CAPD and APD appears to be similar in most of the studies that have looked at that question. In summary, the long-term outcomes of CAPD and APD appear to be similar, and patient and physician preference are likely to increase the utilization of APD in many parts of the world.

scholarly journals Long term outcomes of an Australian TAVI program – better than PARTNER?

2015 ◽  
Vol 24 ◽  
pp. e16
Author(s):  
G. Crouch ◽  
A. Sinhal ◽  
G. Rice ◽  
R. Baker ◽  
J. Bennetts
Keyword(s):  
Long Term Outcomes ◽  
Better Than

scholarly journals Pulmonary Vein Capture is a Predictor for Long-Term Success of Stand-Alone Pulmonary Vein Isolation with Cryoballoon Ablation in Patients with Persistent Atrial Fibrillation

2020 ◽  
Author(s):  
Alexey Babak ◽  
Christine Bienvenue Kauffman ◽  
Cynthia Lynady ◽  
Reginald McClellan ◽  
Kalpathi Venkatachalam ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Pulmonary Vein ◽  
Persistent Atrial Fibrillation ◽  
Cryoballoon Ablation ◽  
Long Term Outcomes ◽  
Initial Strategy ◽  
Study Completion ◽  
Antiarrhythmic Medications ◽  
Better Than

Background: It is unknown whether cryoballoon technology for persistent atrial fibrillation (AF) is a reasonable initial strategy for patients with persistent AF (perAF). Methods: 390 consecutive procedures using cryoballoon for initial AF ablation were evaluated and divided first by clinical presentation: paroxysmal AF (PAF) or perAF, and then whether PV potentials associated PV pacing (PV capture) were identified after ablation. Patients were followed for recurrent AF (median 20 months). Results: PV capture was identified in patients with PAF and perAF (PAF: 20.3% vs. perAF: 14.6%; p < 0.05). No patient charactieristic differences were identified between those patients with or without PV capture. The presence of PV capture was not associated with different outcomes in patients with PAF. However, in patients with perAF, the presence of PV capture was associated with long-term outcomes similar to patients with PAF and significantly better than patients with perAF without PV capture (p < 0.001). In patients with perAF and PV capture, a strategy of reisolation of the PVs only for recurrent AF resulted in 20/23 (87%) patients in sinus rhythm off antiarrhythmic medications at study completion. In patients with PV capture, specific electrophysiologic properties of PV tissue did not have an impact on AF recurrence. Conclusion: PV capture (and not specific PV electrophysiologic characteristics) was associated with decreased recurrent AF in patients with perAF. PV capture may identify those patients with perAF in whom PV isolation alone is sufficient at initial ablation procedure and also as the primary ablation strategy for recurrent AF.

scholarly journals OP0222 IS REFERRING EARLY ARTHRITIS PATIENTS WITHIN 6 WEEKS ASSOCIATED WITH BETTER LONG-TERM OUTCOMES THAN REFERRING WITHIN 12 WEEKS AFTER SYMPTOM ONSET? – INVESTIGATING THE EVIDENCE FOR THE FIRST EULAR RECOMMENDATION FOR EARLY ARTHRITIS IN TWO OBSERVATIONAL COHORTS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 138-138
Author(s):  
E. Niemantsverdriet ◽  
M. Dougados ◽  
B. Combe ◽  
A. Van der Helm - van Mil
Keyword(s):  
Symptom Onset ◽  
Radiographic Progression ◽  
Cox Regression ◽  
Meta Analysis ◽  
Early Arthritis ◽  
Long Term Outcomes ◽  
Research Support ◽  
Meta Analyses ◽  
Better Than

Background:EULAR- recommendations for management of early arthritis formulated that patients should be referred to, and seen by a rheumatologist, within 6-weeks after symptom onset. The mentioned period of ≤6-weeks after symptom onset is shorter than ≤12-weeks, the period that is generally considered as the ‘window-of-opportunity’. Because implementation provides challenges, and evidence supporting that referral ≤6-weeks is better than e.g. <12-weeks is missing, we investigated if ≤6-weeks relates to improved long-term outcomes.Objectives:We used an observational study design to investigate in two cohorts if time-to-encounter (TtE) a rheumatologist ≤6-weeks, compared to 7-12-weeks, results in better disease long-term outcomes, measured with sustained DMARD-free remission (SDFR) and radiographic progression.Methods:Consecutive 1987-RA patients of the Leiden EAC (n=1025) and ESPOIR (n=514) were studied during median 7 and 10 years follow-up. Patients were categorized on duration between symptom onset and first encounter with a rheumatologist; ≤6-, 7-12-, and >12-weeks. Multivariable Cox regression (SDFR), linear mixed models (radiographic progression), and meta-analyses were used.Results:Leiden RA-patients encountered the rheumatologist within 6-weeks obtained SDFR more often than patients seen within 7-12-weeks (HR 1·59, 95%CI:1·02-2·49), and >12-weeks (HR 1·54, 95%CI:1·04-2·29). In ESPOIR, similar but non-significant effects were observed; meta-analysis showed that within 6-weeks was better than 7-12-weeks (HR 1·69, 95%CI:1·10-2·57, Figure 1-A) and >12-weeks (HR 1·67, 95%CI:1·08-2·58). Patients encountered the rheumatologist within 6-weeks had similar radiographic progression than those seen 7-12-weeks, in any cohort, or meta-analysis (Figure 1-B).Figure 1Meta-analyses of time-to-encounter the rheumatologist and the chance of achieving sustained DMARD-free remission (A) and radiographic progression (B)Conclusion:Scientific evidence underlying the first EULAR recommendation depends on the outcome of interest; visiting a rheumatologist within 6-weeks of symptom-onset had clear benefits for achieving SDFR, but not for radiographic progression.References:None.Disclosure of Interests:Ellis Niemantsverdriet: None declared, Maxime Dougados Grant/research support from: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Consultant of: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Speakers bureau: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Bernard Combe Grant/research support from: Novartis, Pfizer, Roche-Chugai, Consultant of: AbbVie; Gilead Sciences, Inc.; Janssen; Eli Lilly and Company; Pfizer; Roche-Chugai; Sanofi, Speakers bureau: Bristol-Myers Squibb; Gilead Sciences, Inc.; Eli Lilly and Company; Merck Sharp & Dohme; Pfizer; Roche-Chugai; UCB, Annette van der Helm - van Mil: None declared

Long-term outcomes of patients with locally advanced bladder cancer that underwent intra-arterial chemotherapy with/without radiotherapy for organ preservation.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 574-574
Author(s):  
Tomohiro Matsuo ◽  
Yasuyoshi Miyata ◽  
Kensuke Mitsunari ◽  
Kojiro Ohba ◽  
Hideki Sakai
Keyword(s):  
Bladder Cancer ◽  
Radical Cystectomy ◽  
Organ Preservation ◽  
Locally Advanced ◽  
Survival Rates ◽  
Long Term Outcomes ◽  
Bladder Preservation ◽  
Advanced Bladder Cancer ◽  
Better Than

574 Background: We previously reported efficacy and safety of intra-arterial chemotherapy with/without radiotherapy in patients with locally advanced bladder cancer. However, there was no data on long-term outcomes, such as organ preservation, subsequently metastasis, and survival of such therapy. In this study, we investigated outcomes of intra-arterial chemotherapy with/without radiotherapy in these patients for long term periods. Methods: In this study, we investigated 129 patients who treated with intra-vesical chemotherapy (n = 50) and intra-arterial chemotherapy and radiotherapy (n = 79). There was no significant difference on age at diagnosis, gender, grade, and T stage between these two groups. Mean/median follow up periods in intra-vesical chemotherapy (n = 50) and intra-arterial chemotherapy with radiotherapy was 86.5/101 and 107.7/122 months. Results: Rates of bladder preservation in intra-arterial therapy and intra-arterial therapy with radiotherapy are 66.0 and 82.3%, respectively (P = 0.035), and Kaplan-Meier survival curves showed that intra-arterial therapy with radiotherapy had better than intra-arterial therapy (P = 0.007). On the other hand, subsequently metastasis-free survival rates in intra-arterial therapy with radiotherapy was significantly better than those with intra-arterial therapy (P = 0.037). Regrading cause-specific survival, the survival period in intra-arterial therapy with radiotherapy was significantly better than that in intra-arterial therapy (P < 0.001). In addition, even if radical cystectomy was performed, the survival rates after the operation in intra-arterial therapy with radiotherapy was significantly better than that in intra-arterial therapy (P = 0.002). There was no sever complication at late phase (over 5 years). Conclusions: Our results showed that intra-arterial therapy with radiotherapy showed better outcomes of bladder preservation, subsequently metastasis, and survival. In addition, in patients locally advanced bladder cancer received radical cystectomy, intra-arterial therapy with radiotherapy had better prognosis compared to intra-arterial therapy.

Thumb carpometacarpal joint total arthroplasty: a systematic review

2015 ◽  
Vol 40 (4) ◽  
pp. 338-350 ◽  
Author(s):  
K. Huang ◽  
N. Hollevoet ◽  
G. Giddins
Keyword(s):  
Systematic Review ◽  
Carpometacarpal Joint ◽  
Long Term Outcomes ◽  
Short Term ◽  
Thumb Carpometacarpal Joint ◽  
Published Evidence ◽  
Total Arthroplasty ◽  
Thumb Carpometacarpal ◽  
Better Than

Thumb carpometacarpal joint total arthroplasty has been undertaken for many years. The proponents believe the short-term outcomes are better than trapeziectomy and its variants, but the longer term complications are often higher. This systematic review of all peer reviewed articles on thumb carpometacarpal joint total arthroplasty for osteoarthritis shows that there are reports of many implants. Some are no longer available. The reported outcomes are very variable: for some there are good long-term outcomes to beyond 10 years; for others there are unacceptably high early rates of failure. Overall the published evidence does not show that total arthroplasty is better than trapeziectomy and its variants yet there is a higher complication rate and significant extra cost of using an implant. Future research needs to compare total arthroplasty with trapeziectomy to assess short term results where the arthroplasties may be better, long-term outcomes and the healthcare and personal costs so that surgeons and patients can make fully informed choices about the treatment of symptomatic thumb carpometacarpal joint osteoarthritis.

Sign in / Sign up

Export Citation Format

Share Document